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http://dxObjective: Despite increasing efforts to prevent infection, the prevalence of hospital-associated Clostridium
difficile infections (CDI) is increasing. Heightened awareness prompted this study of the prevalence and
morbidity associated with CDI after cardiac surgery.
Methods: A total of 22,952 patients underwent cardiac surgery at Cleveland Clinic from January 2005 to
January 2011. CDI was diagnosed by enzyme immunoassay for toxins and, more recently, polymerase chain
reaction (PCR) testing. Hospital outcomes and long-term survival were compared with those of the remaining
population in propensity-matched groups.
Results: One hundred forty-five patients (0.63%) tested positive for CDI at a median of 9 days postoperatively,
135 by enzyme immunoassay and 11 by PCR. Its prevalence more than doubled over the study period. Seventy-
seven patients (48%) were transfers from outside hospitals. Seventy-three patients (50%) were exposed
preoperatively to antibiotics and 79 (56%) to proton-pump inhibitors. Patients with CDI had more baseline co-
morbidities, more reoperations, and received more blood products than patients who did not have CDI. Present-
ing symptoms included diarrhea (107; 75%), distended abdomen (48; 34%), and abdominal pain (27; 19%). All
were treated with metronidazole or vancomycin. Sixteen patients (11%) died in hospital, including 5 of 10 who
developed toxic colitis; 3 of 4 undergoing total colectomy survived. Among matched patients, those with CDI
had more septicemia (P<.0001), renal failure (P ¼ .0002), reoperations (P<.0001), prolonged postoperative
ventilation (P<.0001), longer hospital stay (P<.0001), and lower 3-year survival, 52% versus 64% (P¼ .03),
than patients who did not have CDI.
Conclusions: Although rare, the prevalence of CDI is increasing, contributing importantly to morbidity and
mortality after cardiac surgery. If toxic colitis develops, mortality is high, but colectomy may be lifesaving.
(J Thorac Cardiovasc Surg 2014;148:3157-65)P
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Clostridium difficile infection (CDI), caused by a gram-
positive, spore-forming anaerobic bacillus, is the primary
cause of health care–associated diarrhea,1,2 and in a study
sponsored by the National Institutes of Health, CDI was
found to be the third most common infection occurring in
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The Journal of Thoracic and Caruse of antibiotics, yet despite national and global initiatives
over the last decade for appropriate antibiotic stewardship,
the occurrence of CDI has increased 300% since 1993.2 Re-
ports of a more virulent strain of CDI,4-7 associated patient
morbidity and mortality, and increased resource utilization
have further heightened awareness of this complication.2,8,9
Our objectives were to (1) determine the prevalence of
hospital-acquired CDI after cardiac surgery in our institu-
tion, (2) identify patient characteristics and clinical mani-
festations associated with CDI and its treatment strategies,
and (3) assess morbidity and mortality among patients
with CDI.
PATIENTS AND METHODS
Patients
From January 2005 to January 2011, 22,952 adults underwent cardiac
surgery at Cleveland Clinic. Baseline demographics, comorbidities, and
perioperative variables were obtained from the Heart and Vascular
Institute’s Cardiovascular Information Registry (CVIR). Additional infor-
mation on perioperative antibiotic use, presenting symptoms, and subse-
quent treatment of patients diagnosed with CDI was obtained from
patient medical records and recorded in a REDCap database.10 Cleveland
Clinic’s Institutional Review Board approved the use of these data for
research; patient consent was waived.diovascular Surgery c Volume 148, Number 6 3157
FIGURE 1. Occurrence of in-hospital Clostridium difficile infection
(CDI) after cardiac surgery.
Abbreviations and Acronyms
CDI ¼ Clostridium difficile infection
CVIR ¼ Cardiovascular Information Registry
EIA ¼ enzyme immunoassay
NHLBI ¼ National Heart, Lung, and Blood Institute
PCR ¼ polymerase chain reaction
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MDiagnosis of CDI
CDI was diagnosed by a combination of symptoms and laboratory
testing, supplemented in some cases by colonoscopy and laparotomy.
These clinically diagnosed cases were entered prospectively into Cleveland
Clinic’s Infection Prevention surveillance registry. Before the 2nd quarter
of 2009, an internal definition of hospital-acquired CDI was used that
required a positive enzyme immunoassay (EIA) with onset of diarrhea
more than 72 hours after admission or within 72 hours of discharge, or
the development of pseudomembranous colitis or toxic megacolon more
than 72 hours after admission. Currently, surveillance for hospital-
acquired CDI is routinely performed prospectively using standard defini-
tions.11 Beginning in October 2010, the hospital’s testing platform for
CDI changed from an EIA to a polymerase chain reaction (PCR)–based
one. In this study, the diagnosis was made by EIA in 135 patients and by
PCR in 11. Our yearly incidence density of CDI in the entire hospital
from 2006 through 2013 ranged from 6.1 to 11.9 per 10,000 patient-days
(Table E1).End Points
End points included general complications of cardiac surgery, defined as
for the Society of Thoracic Surgeons National Database (see http://www.
ctsnet.org/filerptDataSpecifications252_1_ForVendorsPGS.pdf), hospital
death, and length of postoperative stay. In addition, specific gastrointestinal
symptoms and signs of CDI, including operations performed for CDI com-
plications and their outcome and time-related mortality, were recorded and
tabulated for patients with CDI.
Follow-up for death was obtained through the CVIR, supplemented with
information from the Social Security Death Master File, queried on
October 27, 2011, before its demise in November 2011.12,13 A lag time
of 6 months resulted in a common closing date of April 27, 2011.
Median follow-up for all patients was 2.5 years, with 25% of patients
followed for more than 4.3 years and 10% more than 5.5 years; 182
patient-years of data were available for analysis in the CDI group. Median
follow-up among CDI survivors was 1.4 years, with 25% followed for
more than 2.5 years and 10% for more than 3.2 years.Data Analysis
Data analysis consisted of describing the prevalence of CDI and identi-
fying its incremental risk factors, then using this information as a basis for
propensity-matched comparison of hospital outcomes and long-term sur-
vival. All analyses were performed using SAS statistical software (SAS
version 9.2; SAS Institute, Inc, Cary, NC).
Prevalence of CDI. Cumulative distribution and probability density
functions were used to describe temporal data related to CDI. The instan-
taneous risk of CDI after cardiac surgery was estimated by a multiphase
hazard model14 in order to determine if risk increased with increasing
length of stay.
Risk factors for CDI. Multivariable logistic regression analysis was
used to identify patient characteristics associated with CDI. Variable selec-
tion from potential risk factors listed in Appendix E1 was by bootstrap ag-
gregation,15,16 using 500 bootstrap samples, automated stepwise
regression, and a P value retention criterion of .05. Thereafter, results3158 The Journal of Thoracic and Cardiovascular Surwere aggregated, and risk factors identified in 50% of analyses were
used to form a parsimonious explanatory model.
This parsimonious model was augmented with preoperative and intra-
operative variables representing patient demography, symptoms, cardiac
and noncardiac comorbidities, procedures, and support, to form a semisa-
turated model (see variables so identified in Appendix E1).
Propensity score development. A propensity score was calcu-
lated for each patient by solving the saturated model for the probability
of being in the CDI group.17-19 Then, using only the propensity score,
patients who did not have CDI were matched 3 to 1 with patients with
CDI using a greedy matching strategy.20 All patients with CDI were
matched. Figure E1 demonstrates that the resulting propensity-matched
CDI and non-CDI groups were well matched.
Comparison of hospital outcomes. Group comparisons were
made using the Wilcoxon rank sum test for continuous data and the c2
test for categorical data (or Fisher exact test when appropriate).
Time-related mortality. Because patients must survive to manifest
CDI, death and CDI are of necessity competing risks. Thus, among
matched patients, life tables were constructed with all at risk of death
initially, with CDI patients censored at the time of diagnosis. Survival of
patients with CDI was then estimated from the date of diagnosis. Nonpara-
metric actuarial survival estimates were obtained using the Kaplan-Meier
method. A parametric method was used to resolve the number of phases
of instantaneous risk of death (hazard function) and to estimate shaping pa-
rameters.14 (For additional details, see www.lerner.ccf.org/qhs/software/
hazard.)
Presentation of Data
Continuous variables are summarized as the mean standard deviation
and as equivalent 15th, 50th (median), and 85th percentiles when distribu-
tions were skewed. Categorical data are summarized by frequencies and
percentages. Uncertainty is expressed by confidence limits equivalent to
 1 standard error (68%).RESULTS
Prevalence and Incidence of CDI
A total of 145 patients (0.63%) developed symptomatic
CDI after cardiac surgery. Its prevalence increased from
2.2 per 1000 patients in 2005 to 11.2 per 1000 patients in
2010 (Figure 1). Median time from surgery to diagnosis
was 9 days (15th and 85th percentiles, 4 and 22 days,gery c December 2014
FIGURE 2. Characterization of onset of Clostridium difficile infection (CDI) after cardiac surgery. A, Distribution of the number of days between cardiac
surgery and diagnosis. B, Instantaneous in-hospital risk of CDI after cardiac surgery. Solid line is parametric hazard enclosed within a dashed 68% con-
fidence band equivalent to 1 standard error (SE). C, Occurrence of CDI. Each symbol represents a diagnosis positioned on the vertical axis by the
Kaplan-Meier estimator, and vertical bars are confidence limits equivalent to1 standard error. Solid line is parametric prevalence enclosed within a dashed
68% confidence band equivalent to 1 SE.
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Mrespectively; range, 2-76 days) (Figure 2, A). However,
when the competing risk of hospital discharge was ac-
counted for, the incidence rose rapidly in the first few
days after surgery, followed by a continued, but lower level,
steady increase among patients with prolonged hospitaliza-
tion (Figure 2, B). This resulted in an estimated in-hospital
prevalence of 0.3% by 7 days, 2.6% by 30 days, and 5.5%
by 60 days (Figure 2, C). Median time from peak white
blood cell count to CDI diagnosis was 3 days (15th and
85th percentiles, 0 and 15 days, respectively; range, 0-70
days) (Figure E2).
Characterization of Patients With CDI
Seventy of the 145 patients with CDI (48%) were trans-
fers from outside hospitals, with a Cleveland Clinic median
preoperative stay of 7 days before surgery (Table 1). Forty-
five patients were hospitalized only at Cleveland Clinic
before surgery, with a median preoperative stay of 6 days,
but 30 had been admitted on the day of surgery. Nine had
undergone a colonoscopy for anemia or gastrointestinal
symptoms before surgery.
Seventy-three patients had received preoperative antibi-
otic treatment for reasons varying from routine dental treat-
ment, urinary tract infection, and respiratory infection to
endocarditis. Seventy-nine were on proton-pump inhibitors,
and 14 were on steroids.
After the heart operation, most patients had a complicated
course. A quarter underwent reoperation for bleeding; 131
required inotropic support, and 61 needed a vasopressor.
Many required extension of antibiotics beyond the 3 stan-
dard doses used for routine prophylaxis, and 96 were started
on a new postoperative antibiotic drug for suspected or veri-
fied infections, including pneumonia, endocarditis, and
wound infections (Table 2). Colonoscopy was required in
4 patients, 2 of whom demonstrated ischemia.
Presenting Symptoms
The presenting symptoms of CDI were diarrhea in 107
patients, distended abdomen in 48, and abdominal pain inThe Journal of Thoracic and Car27 (see Table 1). Forty-eight patients underwent a computed
tomography scan of the abdomen, and 8.5% had radiologic
evidence of colitis, with 6 meeting criteria for pancolitis.
Risk Factors for CDI
Compared with patients who did not have CDI, those
with CDI were older, more symptomatic, and had more co-
morbidities, such as heart failure, treated diabetes, chronic
obstructive pulmonary disease, previous stroke, higher pre-
operative creatinine level, and lower preoperative hemato-
crit, and they were more likely to have been hospital
transfers (Tables 2 and 3). Surgically, they had longer
operative times, longer cardiopulmonary bypass times,
and received more blood products.
Treatment
All 145 patients with CDI were treated with oral or intra-
venous metronidazole, oral vancomycin, or both (oral
metronidazole, 117; intravenous metronidazole, 70; and
oral vancomycin, 66; Table 1). Colonoscopy was performed
in 9 patients, primarily for bleeding; 3 were reported to have
normal results. A clinical picture of toxic colitis developed
in 10; 2 were considered inoperable, 1 declined surgery
(survived), and 7 underwent emergency laparotomy, with
total colectomy in 4 (3 survived), limited resection with
stoma in 1 (died), and exploration only in 2 (1 survived;
the other died).
Outcomes
Patients with CDI had substantially more postoperative
complications than matched patients without CDI,
including strokes, reoperations for bleeding, valve dysfunc-
tion, graft occlusion, and renal failure (Table 3). They also
had more hospital-acquired infections other than CDI, such
as deep sternal wound infections and septicemia. However,
among matched patients, hospital outcomes differed
primarily with respect to the presence of septicemia,
requirement for prolonged ventilation, renal failure, anddiovascular Surgery c Volume 148, Number 6 3159
TABLE 1. Patient, procedure, and treatment characteristics of
patients before and after developing Clostridium difficile infections
(N ¼ 145)
Characteristic
No. of
patients
with data
available No. (%)
Preoperative
History of CDI 145 5 (3.4)
Hospital transfer 145 67 (46)
In ICU before surgery 145 48 (33)
Preoperative antibiotic 145 72 (50)
Reason for antibiotic 72
Urinary tract infection 16 (22)
Respiratory infection 16 (22)
Endocarditis 13 (18)
Dental treatment 8 (11)
Other infection 19 (26)
Proton-pump inhibitor 145 81 (56)
Steroids 145 15 (10)
Immunosuppression (other) 145 7 (4.8)
Bowel preparation within 30 d of surgery 145 15 (10)
Nasogastric tube 145 3 (2.0)
Previous abdominal surgery 145 57 (39)
History of IBD 145 8 (5.5)
Colonoscopy 145 9 (6.2)
Normal 3 (33)
Diverticulosis 4 (44)
Bleeding rectal ulcer 1 (11)
Suspected ischemia 1 (11)
Peri- and postoperative (before CDI diagnosis)
Prophylactic antibiotic extended after 3 doses 145 32 (22)
New postoperative antibiotic 145 96 (66)
Reason for antibiotics 96
High white blood cell count 71 (74)
Fever 36 (38)
Pneumonia 32 (33)
Reoperation for bleeding 23 (24)
Wound infection 14 (15)
Endocarditis 13 (13)
Other 40 (42)
Inotrope 145 132 (91)
Vasopressor 145 62 (43)
Tracheostomy 145 41 (28)
Bleeding/reexploration 145 35 (24)
Colonoscopy 145 4 (2.8)
Ischemia 2 (50)
Polyp 1 (25)
Normal 1 (25)
Symptoms and diagnosis of CDI
Diarrhea 145 109 (75)
Abdominal distension 145 49 (34)
Fever 145 47 (32)
Abdominal pain 145 27 (19)
CT scan 145 48 (33)
Colitis 14 (29)
Pancolitis 6 (13)
(Continued)
TABLE 1. Continued
Characteristic
No. of
patients
with data
available No. (%)
Free air 0 (0)
Distended bowel 13 (27)
Normal 15 (31)
Management of CDI
Antibiotics* 145 145 (100)
Oral flagyl 117 (81)
Intravenous flagyl 70 (48)
Oral vancomycin 66 (46)
Colonoscopy 145 9 (6.2)
Colitis 2 (22)
Rectal ulcer 1 (11)
Diverticula and AVMs 1 (11)
AVMs 2 (22)
Normal or nonspecific 3 (44)
Surgery/laparotomy 145 7 (4.8)
Limited bowel resection with stoma 1 (14)
Colectomy 4 (57)
Exploration 2 (29)
Microscopy (operative specimen) 145 5 (3.4)
Pseudomembranous colitis 3 (60)
Ischemic colitis 1 (20)
Cytomegalovirus 1 (20)
CDI, Clostridium difficile infection; ICU, intensive care unit; IBD, inflammatory
bowel disease; CT, computed tomography; AVMs, arteriovenous malformations.
*Not mutually exclusive.
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Mreoperation for bleeding. Resource utilization was high, as
reflected in longer duration of postoperative ventilatory sup-
port, and longer stays in the intensive care unit and in hos-
pital (Table 4). In-hospital mortality was higher among
patients with CDI (11%), particularly if toxic colitis devel-
oped (50%, see earlier), but was similar among matched
patients.
Survival after diagnosis of CDI at 30 days, 6 months, and
1, 2, and 3 years was 88%, 70%, 63%, 59%, and 52%,
respectively (Figure E3). Survival among matched patients
without CDI at the same intervals was 90%, 82%, 77%,
70%, and 64% (P ¼ .03 by time-varying covariable anal-
ysis; Figure 3), with a prolonged higher risk of death for
at least 6 months.DISCUSSION
Prevalence and Incidence of CDI
We report an increasing prevalence of CDI that parallels
national and global trends.2 In part, this may reflect more
sensitive testing, but the increase in prevalence was evident
a year before PCR techniques supplanted EIA, and the in-
crease was greater for patients undergoing cardiac surgery
than for the hospital as a whole (Table E1).
Although time to diagnosis peaked at 6 to 7 days after
surgery then decreased sharply, this does not take intogery c December 2014
TABLE 2. Patient and procedure characteristics: before matching and matched groups
Variable
No CDI: before matching (n ¼ 22,807) CDI (n ¼ 145) No CDI: matched (n ¼ 435)
No. of
patients
with data
available
No. (%) or
mean ± SD P*
No. of
patients
with data
available
No. (%) or
mean ± SD Py
No. of
patients
with data
available
No. (%) or
mean ± SD
Demographics
Age (y) 22,807 63  14 .001 145 67  14 .7 435 67  14
Female 22,807 7818 (34) .15 145 58 (40) >.9 435 174 (40)
Race 22,634 145 434
White 20,145 (89) .18 124 (86) .6 379 (87)
Black 1425 (6.3) .10 14 (9.7) .6 36 (8.3)
Other 1064 (4.7) >.9 7 (4.8) .8 19 (4.4)
Body surface area (m2) 22,241 2.02  0.28 .4 144 2.01  0.29 .3 425 1.98  0.28
Hospital transfer 22,671 4788 (21) <.0001 145 70 (48) .8 435 206 (47)
Symptoms
NYHA functional class 22,588 <.0001 145 .8 434
I 6141 (27) 21 (14) 55 (13)
II 9555 (42) 47 (32) 156 (36)
III 5573 (25) 54 (37) 147 (34)
IV 1319 (5.8) 23 (16) 78 (18)
Emergency surgery 21,882 .8 145 5 (3.4) .4 421 22 (5.2)
Cardiac comorbidity
LVEF (%) 14,323 51  13 .002 57 43  17 .5 192 45  16
Myocardial infarction 22,807 5829 (26) .01 145 50 (34) .4 435 134 (31)
Heart failure 22,787 6081 (27) <.0001 145 67 (46) .8 435 195 (45)
Endocarditis 22,788 1250 (5.5) .3 145 11 (7.6) .7 435 37 (8.5)
Previous cardiac surgery 22,802 6365 (28) .3 145 46 (32) .7 435 145 (33)
Noncardiac comorbidity
Hypertension 22,788 15,974 (70) .7 145 104 (72) .8 435 307 (71)
Stroke 22,807 2161 (9.5) .004 145 24 (17) .8 435 69 (16)
Pharmacologically treated diabetes 22,566 4530 (20) .008 141 41 (29) .5 434 114 (26)
PAD 22,807 2220 (9.7) .10 145 20 (14) .9 435 62 (14)
COPD 22,787 3445 (15) <.0001 145 48 (33) .9 435 147 (34)
Smoking 22,701 12,181 (54) .11 144 87 (60) .6 434 272 (63)
Creatinine (mg/dL) 22,786 1.2  0.90 <.0001 145 1.6  1.3 .5 434 1.5  1.3
Renal dialysis 22,787 387 (1.7) <.0001 145 9 (6.2) .15 435 15 (3.4)
Hematocrit (%) 22,801 38  6.3 <.0001 145 35  6.0 >.9 434 35  6.4
Procedure
Isolated CABG 22,807 3940 (17) .7 145 23 (16) .8 435 72 (17)
Isolated valve 22,807 6918 (30) .07 145 34 (23) .4 435 88 (20)
Combined CABG/valve 22,807 3283 (14) .002 145 34 (23) .6 435 92 (21)
Aortic root, ascending aorta 22,807 3990 (17) .6 145 23 (16) .2 435 89 (20)
Other cardiac 22,807 4676 (21) .8 145 31 (21) .9 435 94 (22)
Surgical invasiveness 22,042 145 419
Full incision 17,818 (81) <.0001 136 (94) .6 398 (95)
Minimal 3130 (14) .006 9 (6.2) .14 14 (3.3)
Percutaneous/ports 1094 (4.8) .007 0 (0) .19 7 (1.7)
CPB time (min) 22,807 95  55 <.0001 145 128  58 .16 435 120  65
Myocardial ischemic time (min) 22,807 69  42 .0004 145 83  53 .19 435 77  50
Intra-/postoperative IABP 22,807 566 (2.5) <.0001 145 17 (12) .3 435 39 (9.0)
Blood product use 22,807 11,456 (50) 145 134 (92) 435 386 (89)
RBC transfusion 10,491 (46) <.0001 128 (88) .18 364 (84)
FFP 4869 (21) <.0001 84 (58) .03 206 (47)
CDI,Clostridium difficile infection; SD, standard deviation;NYHA, NewYork Heart Association; LVEF, left ventricular ejection fraction; PAD, peripheral arterial disease;COPD,
chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; IABP, intra-aortic balloon pump; RBC, red blood cell; FFP, fresh
frozen plasma. *Unmatched versus CDI. yMatched versus CDI.
Keshavamurthy et al Perioperative Management
The Journal of Thoracic and Cardiovascular Surgery c Volume 148, Number 6 3161
P
M
TABLE 3. Incremental risk factors for Clostridium difficile infection
Risk factor Estimate ± SE Odds ratio (68% CLs) P Reliability (%)*
Demographics
Older agey 0.21  0.092 See Figure E4, A .02 50
Hospital transfer 0.44  0.179 1.5 (1.3, 1.8) .006 71
Comorbidities
Lower HDL 0.021  0.0065 See Figure E4, B .001 67
Increased creatininez 0.36  0.158 See Figure E4, C .02 51
COPD 0.71  0.182 2.0 (1.7, 2.4) <.0001 90
Hypertension (less risk) 0.45  0.196 0.64 (0.52, 0.77) .02 58
Procedural
Insertion of temporary mechanical assist device 0.94  0.23 2.9 (2.4, 3.7) <.0001 93
Blood use intra- or postoperatively 1.3  0.37 3.9 (2.7, 5.6) .0003 80
Intra- and postoperative cardiac RBC transfusion unitsx 0.44  0.110 See Figure E4, D <.0001 59
More recent date of operation 0.32  0.057 See Figure E4, E <.0001 99
Intercept 7.83  0.56 <.0001 –
C-statistic ¼ 0.85. SE, Standard error; CL, confidence limits; HDL, high-density lipoprotein cholesterol; COPD, chronic obstructive pulmonary disease; RBC, red blood cell.
*Percent of times factor appeared in 500 bootstrap models. yExp(age/50), exponential transformation. zLog(creatinine), logarithmic transformation. xLog(RBC units), logarith-
mic transformation.
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Maccount the rapidly diminishing number of patients not yet
discharged after 7 days. The hazard function accounts for
this and demonstrates that risk of CDI continues to increase
the longer a patient is hospitalized. As a result, cumulative
incidence of CDI increases exponentially to more than 5%
at 60 days. Although an inference might be that continued
hospital exposure is the cause of this increasing incidence,
we caution the reader that we do not know whether patients
who did not have CDI may have been diagnosed with CDI
after hospital discharge. The National Heart, Lung, and
Blood Institute (NHLBI)-funded Cardiothoracic Surgery
Clinical Trials Network infection study, which extended
to 60 days beyond hospital discharge, showed that nearly
half the infections occurred after discharge. Thus, theTABLE 4. Outcomes before matching with and without CDI, and matched
Variable
No CDI: before matching (n ¼ 22,80
No. (%) or mean ± SD P*
Complications
Septicemia 562 (2.5) <.00
Deep sternal wound infection 148 (0.70) .07
Hospital death 820 (3.6) <.00
Permanent stroke 427 (1.9) .00
Perioperative MI 66 (0.30) .5
Atrial fibrillation 5509 (24) .00
Ventilation>24 h 4299 (19) <.00
Renal failure requiring dialysis 615 (2.7) <.00
Reoperation for bleeding 1100 (4.8) <.00
Lengths of stayz
ICU (h)x 40 (22, 126) <.00
Postoperative (d)x 7.1 (4.9, 15) <.00
Hospital (d)x 9.0 (5.3, 21) <.00
CDI, Clostridium difficile infection; SD, standard deviation;MI, myocardial infarction; ICU
85th percentiles). xNo CDI: before matching group. Data available for 22,660 patients.
3162 The Journal of Thoracic and Cardiovascular Surgeneral pattern of incidence of infection, including CDI,
is unclear because these late infections have not previously
been studied.
The epidemiology of CDI has changed over time, with re-
ports of a previously uncommon and more virulent strain,
BI/NAP1/027, increasingly associated with disease out-
breaks.4-7 This strain is characterized by a 16- to 23-fold in-
crease in production of toxins A and B.7 Hypervirulence is
manifested clinically by a high fever, unstable hemody-
namics, and the development of toxic megacolon.8 Some
have hypothesized that widespread use of fluoroquinolone
antibiotics may have selectively allowed for proliferation
of this strain.11 We do not know how many of our patients
with CDI had this strain.group
7) CDI (n ¼ 145) No CDI: matched (n ¼ 435)
No. (%) or mean ± SD Py No. (%) or mean ± SD
01 19 (13) <.0001 15 (3.4)
3 (2.1) .4 4 (0.92)
01 16 (11) .8 44 (10)
1 8 (5.5) .3 15 (3.4)
0 (0) >.9 2 (0.46)
01 55 (38) .07 130 (30)
01 96 (66) <.0001 194 (45)
01 24 (17) .002 33 (7.6)
01 20 (14) .03 34 (7.8)
01 264 (69, 801) <.0001 90 (24, 281)
01 21 (10, 49.5) <.0001 11 (6.1, 26)
01 27 (13, 59) <.0001 16 (8.0, 36)
, intensive care unit. *Unmatched versus CDI. yMatched versus CDI. zMedian (15th,
gery c December 2014
FIGURE 3. Survival of propensity-matched patients stratified by whether
or not the patient had a Clostridium difficile infection (CDI). Time zero for
the upper curve is the date of surgery, with patients censored at occurrence
of CDI (competing-risks analysis). Time zero for the lower curve is the time
of CDI diagnosis. Each symbol represents a death, vertical bars are 68%
confidence limits equivalent to 1 standard error, and solid lines are para-
metric estimates enclosed within a 68% confidence band.
Keshavamurthy et al Perioperative Management
P
MCharacteristics of Patients With CDI and Risk
Factors for CDI
Our patients with CDI had several previously well-
described risk factors, including previous exposure to antibi-
otics,8,21,22 preoperative hospitalization, and longer duration
of hospitalization.23,24 Half had been treated with broad-
spectrum antibiotics before the CDI diagnosis.21,22,25,26
More than half were on a proton-pump inhibitor, which is
linked to increased occurrence of CDI.27-29 Increased
gastric pH allows survival of CDI spores.28,29
Other known risk factors illustrated by our study included
older age1,2,8,21,22,26 and previous colonoscopy or gastro-
intestinal surgery1,21,28; some patients were immuno-
compromised.1,9,28 Patients with CDI also had a high
comorbidity burden, which is associated with greater
susceptibility to CDI.30,31
Only 5 of our patients had a history of CDI, and none had
been diagnosed as carriers.32 This may suggest that symp-
tomless colonization with C difficile is protective and asso-
ciated with a reduced risk for C difficile–associated
diarrhea. Others have noted that an alteration in normal
fecal flora, followed by colonization with C difficile and
subsequent release of toxins, are necessary steps in the
development of C difficile diarrhea.33
Although a limitation of our study is that previous antibi-
otic use, previous gastrointestinal surgery, immunocompro-
mise, and proton-pump inhibitor use were known only for
CDI patients, surrogates for this, such as hospital transfer
status, chronic pulmonary disease, and some comorbidities
known for all patients, were associated with the occurrence
of CDI. However, during multivariable analysis, it was
evident that surgical factors such as blood product use and
the need to insert a temporary circulatory assist deviceThe Journal of Thoracic and Carwere powerful risk factors. Both cardiopulmonary bypass
and blood product use are associated with alterations in
immunology and elaboration of cytokines.34 Both have
the potential to raise levels of free iron, which is associated
with infection.35 We have investigated these associations
in detail at this institution, particularly red blood cell trans-
fusion,36 and our findings have been corroborated by the
NHLBI-funded Cardiothoracic Surgery Clinical Trials
Network postcardiac surgery infection study.3 The mecha-
nism remains elusive, but it further emphasizes the value
of blood conservation and protocols to reduce intraopera-
tive bleeding and the use of blood products. The study
also highlights the vulnerability of patients who require
temporary circulatory support after cardiac surgery, with
the potential for gut ischemia from low cardiac output.
Presentation and Diagnosis
More than 70% of our patients presented with diarrhea,
as well as abdominal pain, distension, and leukocytosis. Cy-
totoxins produced by C difficile lead to symptoms, typically
within 48 to 72 hours of infection.21
Laboratory diagnosis of CDI involved testing for stool
toxins and, less commonly, stool cultures. Our change in
the testing platform from EIA to PCR was based on the
Hookman and Barkin21 report of laboratory testing for
CDI: EIA, 73% sensitivity, 98% specificity; real-time
PCR, 93% sensitivity, 97% specificity; cell culture assay,
77% sensitivity, 97% specificity; and anaerobic culture
for toxigenic C difficile strains, 100% sensitivity, 96%
specificity. Although stool cultures are sensitive tests, they
are associated with long turnaround times compared with
the relatively rapid turnaround times for PCR testing.37 If
colonoscopy is performed, it may demonstrate colonic
inflammation and, if CDI is advanced, may show the pres-
ence of pseudomembranes, diagnostic for CDI.38 The fact
that only one third of the patients had a computed tomogra-
phy scan and only 9 had a colonoscopy, and one third of
these examinations were read as normal, strongly suggests
that the abdominal presentation of CDI was relatively
benign in most patients.
Treatment
All our patients were treated with antibiotic therapy (van-
comycin, metronidazole, or both). Patients with clinical
symptoms of toxic colitis were offered surgery if operable.
Three of 4 patients undergoing colectomy survived.
We have not tried treatment with monoclonal antibodies
against C difficile toxins, which has been reported to be
successful.39 Nor have we used nitazoxanide and rifaximin,
fidaxomicin, probiotics, or anionic polymers, as suggested
by others.8,38 Antibiotic treatment does not reestablish
normal flora in the bowel; hence, some advocate fecal
bacteriotherapy for patients with chronic relapsing CDI
who fail conventional treatment.9,40-42diovascular Surgery c Volume 148, Number 6 3163
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CDI was associated with increased hospital morbidity,
mortality, and resource utilization, and prolonged high
risk of death for least 6 months after surgery. Complications
related to CDI led in part to this increased use of resources
via the need for additional surgical procedures, pharmaco-
therapy, and increased length of stay. However, in most of
our cases, the CDI manifestations were benign and the
CDI was just another marker of the severity of comorbid-
ities and patient and operative complexity.43 In other gen-
eral hospital settings, higher mortality, longer lengths of
stay, and higher costs have been documented.44Clinical Implications
The increasing prevalence of CDI after heart surgery is
concerning and costly, and more effective efforts to limit
its spread are needed. Our study has shown that the complex
and complicated patients are most vulnerable.
The mode of CDI transmission is via the fecal-oral
route of C difficile spores; hence, vigilance regarding envi-
ronmental reservoirs, including asymptomatic C difficile
carriers, is warranted. C difficile spores are resilient and
can survive on surfaces for months despite standard sterili-
zation treatments.21,38 We believe that a high level of
suspicion plus early diagnosis and treatment can reduce
the deleterious consequences.Strengths and Limitations
This study was conducted in a quaternary care setting
with high-acuity patients undergoing cardiac surgery,
20% of whom were transferred from other hospitals.
Thus, our findings may not be generalizable to other set-
tings. One strength of our study is the detailed information
available case by case for patients with CDI, which cannot
be achieved with purely administrative data. However, as
noted earlier, many traditional risk factors for CDI were
not available for the patients without CDI. Toward the end
of the study period, diagnostic testing evolved, and it is
not clear how this affected the detection of CDI. We also
recognize that CDI cannot be randomized, and the use of
propensity score methods for so-called natural experiments
such as this may be considered controversial by some. We
believe, however, that risk adjustment is superior to multi-
variable analysis of outcomes.18CONCLUSIONS
CDI is an important contributor to morbidity and mortal-
ity after cardiac surgery, and the risk of CDI increases dur-
ing prolonged hospitalization. Although risk factors such as
prolonged hospitalization, antibiotics, proton-pump inhibi-
tors, comorbidities, and high-risk operations were common
among patients with CDI, the strongest risk factors in this
setting were perioperative ones, including blood product3164 The Journal of Thoracic and Cardiovascular Suruse and the need for temporary circulatory support. If toxic
colitis develops, mortality is high, but colectomy may be
lifesaving.References
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MAPPENDIX E1. VARIABLES CONSIDERED IN THE
ANALYSES
Demographic
Age (years),* gender,* race (white/black/other),* weight
(kg), height (cm), weight/height ratio, body surface area
(m2), body mass index (kg/m2).*
Symptoms and Status
New York Heart Association functional class (I-IV),*
emergency operation,* hospital transfer.*
Cardiac Comorbidity
Previous myocardial infarction,* atrial fibrillation,*
complete heart block or pacer, ventricular arrhythmia, heart
failure,* endocarditis,* coronary artery disease (number of
systems 50%),* previous cardiac operation,* surgery
number.
Noncardiac Comorbidity
Peripheral arterial disease,* carotid disease,* hyperten-
sion,* pharmacologically treated diabetes,* insulin-treated
diabetes,* non–insulin-dependent diabetes, chronic
obstructive pulmonary disease,* history of smoking,* pre-
operative renal dialysis,* previous stroke,* creatinine
(mg/dL),* blood urea nitrogen (mg/dL), bilirubin
(mg/dL),* creatinine clearance, glomerular filtration rate,
hematocrit (%),* total cholesterol (mg/dL), high-density*Variables used in the propensity model.
3165.e1 The Journal of Thoracic and Cardiovascular Surlipoprotein cholesterol (mg/dL),* low-density lipoprotein
cholesterol (mg/dL), triglycerides (mg/dL).Experience
Date of operation (years since January 1, 2005),* surgeon.*Procedural
Coronary artery bypass grafting,* number of internal
thoracic arteries used,* aortic valve procedure,*mitral valve
procedure,* tricuspid valve procedure,* aortic procedure,
septal myectomy,* mechanical assist device,* transplant,*
surgical invasiveness (full,* minimal, percutaneous/ports).Support
On-pump,* cardiopulmonary bypass time (minutes),*
aortic clamp used,* aortic clamp time (minutes), circulatory
arrest,* circulatory arrest time (minutes), total operating
room time (minutes).*Blood Use
Intraoperative: red blood cell units, platelets, fresh frozen
plasma, cryoprecipitate, any intraoperative blood use. Post-
operative: red blood cell units,* platelets, fresh frozen
plasma, cryoprecipitate, any postoperative blood use. Total:
red blood cell units,* platelets, fresh frozen plasma, cryo-
precipitate, any intraoperative or postoperative blood use.*gery c December 2014
FIGURE E2. Characterization of the onset of Clostridium difficile infection (CDI) after cardiac surgery. Days between peak white blood cell (WBC) count
and diagnosis of CDI.
FIGURE E1. Covariable balance description before (triangles) and after (squares) matching between the no CDI and CDI groups.* HDL, High-density
lipoprotein; LVEF, left ventricular ejection fraction; clr, clearance; IDDM, insulin-dependent diabetes; CABG, coronary artery bypass grafting; CAD, cor-
onary artery disease; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; CPB, cardiopulmo-
nary bypass;OR, operating room; CDI, Clostridium difficile infection. *Austin PC, Mamdani MM. A comparison of propensity score methods: a case study
estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25:2084-106.
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FIGURE E3. Unadjusted survival stratified by whether or not the patient had a Clostridium difficile infection (CDI). Time zero for the upper curve is the
date of surgery, with patients censored at occurrence of CDI. Time zero for the lower curve is the time of the CDI diagnosis. Each symbol on the lower curve
represents a death positioned on the vertical axis by the Kaplan-Meier estimator, and vertical bars are confidence limits equivalent to1 standard error. The
solid line for both curves is parametric survival enclosed within a dashed 68% confidence band. The number of patients at risk is given below the horizontal
axis.
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FIGUREE4. Effect of continuous risk factors on the probability of developingClostridium difficile (CDI) infection using nomograms of the logistic regres-
sion equation. Solid lines are parametric estimates enclosed within a 68% confidence band. Simulations are based on the logistic model (Table 3) for a 65-
year-old patient with hypertension, no chronic obstructive pulmonary disease, high-density lipoprotein (HDL) level 48mg/dL, creatinine level 1.0mg/dL, no
hospital transfer, and no ventricular assist device, stratified by use of blood products. A, Age at operation. B, Preoperative HDL level. C, Preoperative creat-
inine level. D, Red blood cell (RBC) units transfused. E, Date of operation.
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TABLE E1. Hospital-wide occurrence of Clostridium difficile infection
per 10,000 patient-days
Year Number Patient-days Rate per 10,000 patient-days
2006 203 332,119 6.11
2007 191 333,758 5.72
2008 209 339,221 6.16
2009 204 356,612 5.72
2010 264 348,522 7.57
2011 409 343,073 11.92
2012 368 361,681 10.17
2013 317 358,587 8.84
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